Parkinson’s
Pharmaceutical company AbbVie has announced positive topline results from its Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose [...]
A study has revealed that Parkinson's disease patients using a telemonitoring device saw improved or stable symptom manifestation. The study investigated the progression of Parkinson's symptoms over two years for 17 patients who were previously evaluated using traditional methods. Physicians integrated PDMonitor, a telemonitoring device developed by PD Neurotechnology, for each patient and used it [...]
An early-stage Parkinson's vaccine called ACI-7104 has shown positive interim safety and immunogenicity data from a Phase 2 clinical trial. The vaccine is an active immunotherapy which has generated a target-specific antibody response against pathological oligomeric alpha-synuclein to inhibit spreading and downstream neurodegeneration in early Parkinson’s disease. The accumulation of alpha-synuclein (a-syn) protein aggregates has [...]
Alamar Biosciences has announced a strategic collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to accelerate biomarker discovery and improve our understanding of Parkinson's disease (PD). This collaboration aims to address the critical need for robust biological classification of PD and related neurodegenerative diseases. By leveraging Alamar's advanced proteomics platform, the team [...]
Charity Parkinson's UK has partnered with England Boxing to coach more instructors and trainers to deliver non-contact boxing for people with the condition. England Boxing have been awarded £17,000 in funding from Parkinson's UK and St Paul's Boxing Club in Hull to start the new coaching programme. The programme will give boxing providers and gyms [...]
Brain disorders like Parkinson’s (PD) or Alzheimer’s Disease (AD) start to develop in patients much earlier than when their first clinical symptoms appear. Treating patients at these early stages could slow or even stop their disease, but there is currently no way to diagnose brain disorders at those pre-symptomatic stages. Thus far, the specific brain [...]
An app which tracks activity in Parkinson's patients has been found to help reduce hospital A&E visits, increase exercise and improve medication adherence. Precision medicine firm Rune Labs' StrivePD platform has been trialled for 10 months in 138 Parkinson's patients at a clinic in California. The patients had an age range of 39 to 88 [...]
An efficient and robust system using the C. elegans nematode to screen for compounds that can stop the growth of amyloid proteins has been developed by a team of University of Toronto researchers. Through their own screen of over 2,500 compounds, the team found 40 that demonstrate the ability to inhibit amyloid formation. Amyloid proteins [...]
Global think tank the Milken Institute has published an action plan on how to better harness AI and precision medicine to address neurodegenerative disease. The report aims to serve as a resource for patient advocates, philanthropists, researchers, policymakers, and industry to work together to accelerate the ethical adoption of these emerging technologies for maximum impact. [...]
Novel magnetic nanodiscs could provide a much less invasive way of stimulating parts of the brain, paving the way for stimulation therapies without implants or genetic modification, MIT researchers report. The scientists envision that the tiny discs, which are about 250 nanometres across - about 1/500 the width of a human hair - would be [...]
